JP7545955B2 - インフルエンザｈａスプリットワクチンの製造方法 - Google Patents

インフルエンザｈａスプリットワクチンの製造方法 Download PDF

Info

Publication number
JP7545955B2
JP7545955B2 JP2021504119A JP2021504119A JP7545955B2 JP 7545955 B2 JP7545955 B2 JP 7545955B2 JP 2021504119 A JP2021504119 A JP 2021504119A JP 2021504119 A JP2021504119 A JP 2021504119A JP 7545955 B2 JP7545955 B2 JP 7545955B2
Authority
JP
Japan
Prior art keywords
influenza
split vaccine
split
vaccine
producing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021504119A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020179797A5 (https=
JPWO2020179797A1 (https=
Inventor
宜聖 高橋
悠 安達
学 阿戸
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DIRECTOR-GENERAL NATIONAL INSTITUTE OF INFECTIOUS DISEASES
Sumitomo Pharma Co Ltd
Original Assignee
DIRECTOR-GENERAL NATIONAL INSTITUTE OF INFECTIOUS DISEASES
Sumitomo Dainippon Pharma Co Ltd
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DIRECTOR-GENERAL NATIONAL INSTITUTE OF INFECTIOUS DISEASES, Sumitomo Dainippon Pharma Co Ltd, Sumitomo Pharma Co Ltd filed Critical DIRECTOR-GENERAL NATIONAL INSTITUTE OF INFECTIOUS DISEASES
Publication of JPWO2020179797A1 publication Critical patent/JPWO2020179797A1/ja
Publication of JPWO2020179797A5 publication Critical patent/JPWO2020179797A5/ja
Application granted granted Critical
Publication of JP7545955B2 publication Critical patent/JP7545955B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2021504119A 2019-03-04 2020-03-03 インフルエンザｈａスプリットワクチンの製造方法 Active JP7545955B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019038662 2019-03-04
JP2019038662 2019-03-04
PCT/JP2020/008974 WO2020179797A1 (ja) 2019-03-04 2020-03-03 インフルエンザｈａスプリットワクチンの製造方法

Publications (3)

Publication Number Publication Date
JPWO2020179797A1 JPWO2020179797A1 (https=) 2020-09-10
JPWO2020179797A5 JPWO2020179797A5 (https=) 2023-08-03
JP7545955B2 true JP7545955B2 (ja) 2024-09-05

Family

ID=72337458

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021504119A Active JP7545955B2 (ja) 2019-03-04 2020-03-03 インフルエンザｈａスプリットワクチンの製造方法

Country Status (15)

Country Link
US (1) US12491240B2 (https=)
EP (1) EP3936147A4 (https=)
JP (1) JP7545955B2 (https=)
KR (1) KR20210135261A (https=)
CN (1) CN114096273B (https=)
AU (1) AU2020233456B2 (https=)
BR (1) BR112021017310A8 (https=)
CA (1) CA3132578A1 (https=)
EA (1) EA202192398A1 (https=)
IL (1) IL285984A (https=)
MX (1) MX2021010685A (https=)
MY (1) MY208974A (https=)
PH (1) PH12021552094A1 (https=)
SG (1) SG11202109566XA (https=)
WO (1) WO2020179797A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3107409A1 (en) 2018-07-23 2020-01-30 Japan As Represented By Director General Of National Institute Of Infectious Diseases Composition containing influenza vaccine
KR20220098370A (ko) * 2019-11-07 2022-07-12 세퀴러스 유케이 리미티드 감소된 입자 크기를 가지는 바이러스 백신을 제조하기 위한 조성물 및 방법
CN121816361A (zh) 2023-04-26 2026-04-07 国立健康危机管理研究机构 抗流感抗体

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2374894B1 (en) * 1993-09-13 2014-09-17 Protein Sciences Corporation A method for producing influenza hemagglutinin multivalent vaccines
US8278083B2 (en) 2004-03-22 2012-10-02 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inactivated influenza virus compositions
US20230201329A1 (en) * 2006-07-17 2023-06-29 Glaxosmithkline Biologicals Sa Influenza vaccine
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
JPWO2008114819A1 (ja) 2007-03-20 2010-07-08 大日本住友製薬株式会社 新規アデニン化合物
PE20090146A1 (es) * 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
JP5518041B2 (ja) * 2008-03-18 2014-06-11 ノバルティス アーゲー インフルエンザウイルスワクチン抗原の調製における改良
CA2731686C (en) 2008-07-25 2020-04-07 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
WO2010047509A2 (ko) 2008-10-24 2010-04-29 아주대학교 산학협력단 친화도와 안정성이 향상된 항 ｄｒ5 항체, 및 이를 포함하는 암 예방 또는 치료용 조성물
CN102223895B (zh) * 2008-11-25 2014-11-05 巴克斯特保健股份有限公司 生产pH稳定的包膜病毒的方法
CN101524538A (zh) 2009-03-26 2009-09-09 成都康华生物制品有限公司 一种流感-大流行流感二价联合疫苗及其制备方法
EP2536425B1 (en) 2010-02-18 2019-06-19 Icahn School of Medicine at Mount Sinai Vaccines for use in the prophylaxis and treatment of influenza virus disease
EP3098236A1 (en) 2010-03-08 2016-11-30 Celltrion, Inc. Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
BR112013025254A2 (pt) 2011-04-21 2016-09-06 Baxter Internat Inc E Baxter Healthcare S A método para isolar um antígeno de uma composição de vacina
CN102406931B (zh) * 2011-11-25 2014-02-05 成都康华生物制品有限公司 大流行流感病毒裂解疫苗
WO2013173256A2 (en) * 2012-05-16 2013-11-21 Kj Biosciences, Llc New and improved influenza vaccines
KR20140118682A (ko) 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
AU2015305690A1 (en) 2014-08-18 2017-03-02 Sanofi Pasteur Inc. Alkylated influenza vaccines
US11191727B2 (en) 2014-12-31 2021-12-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Multivalent nanoparticle-based vaccines
JP2018517405A (ja) * 2015-05-04 2018-07-05 エピバックス インコーポレーテッド インフルエンザａ／上海／２／２０１３ ｈ７配列の改変ｈ７赤血球凝集素糖タンパク質
CN108348618B (zh) * 2015-09-29 2021-06-15 大日本住友制药株式会社 腺嘌呤缀合物化合物及其作为疫苗佐剂的用途
EP3603619B1 (en) * 2017-03-29 2025-08-13 Sumitomo Pharma Co., Ltd. Vaccine adjuvant formulation
WO2019045090A1 (ja) * 2017-09-04 2019-03-07 公益財団法人ヒューマンサイエンス振興財団 インフルエンザｈａスプリットワクチンの製造方法
JP7403733B2 (ja) 2017-09-04 2023-12-25 国立感染症研究所長 インフルエンザｈａスプリットワクチンの製造方法
CA3107409A1 (en) 2018-07-23 2020-01-30 Japan As Represented By Director General Of National Institute Of Infectious Diseases Composition containing influenza vaccine
CA3121613A1 (en) * 2018-12-26 2020-07-02 Sumitomo Dainippon Pharma Co., Ltd. Preparation including vaccine adjuvant
JP2022521760A (ja) * 2019-02-28 2022-04-12 ノババックス，インコーポレイテッド Ｒｓｖ感染によって引き起こされる疾患又は障害を予防する方法

Also Published As

Publication number Publication date
MX2021010685A (es) 2021-12-10
CA3132578A1 (en) 2020-09-10
AU2020233456A1 (en) 2021-10-07
EP3936147A1 (en) 2022-01-12
CN114096273A (zh) 2022-02-25
WO2020179797A1 (ja) 2020-09-10
US12491240B2 (en) 2025-12-09
IL285984A (en) 2021-10-31
EA202192398A1 (ru) 2021-11-23
AU2020233456B2 (en) 2026-04-09
US20220152191A1 (en) 2022-05-19
MY208974A (en) 2025-06-14
BR112021017310A2 (https=) 2021-11-16
PH12021552094A1 (en) 2022-05-30
JPWO2020179797A1 (https=) 2020-09-10
CN114096273B (zh) 2026-03-17
EP3936147A4 (en) 2022-09-28
BR112021017310A8 (pt) 2022-12-06
SG11202109566XA (en) 2021-10-28
KR20210135261A (ko) 2021-11-12

Similar Documents

Publication Publication Date Title
US12527857B2 (en) Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
JP7403733B2 (ja) インフルエンザｈａスプリットワクチンの製造方法
JP7545955B2 (ja) インフルエンザｈａスプリットワクチンの製造方法
JP7382634B2 (ja) 交差免疫抗原ワクチン及びその調製方法
US20230406910A1 (en) Method for producing influenza ha split vaccine
WO2025092866A1 (zh) 一种多价流感mRNA疫苗
TWI857017B (zh) 流感ha裂解疫苗之製造方法
CN115850395A (zh) 一种流感病毒通用型纳米颗粒疫苗及其制备方法
EA045912B1 (ru) Способ приготовления сплит-вакцины на основе гемагглютинина гриппа
HK40068192A (en) Method for preparing influenza ha split vaccine
HK40032891A (en) Method for producing influenza ha split vaccine
EA045852B1 (ru) Способ получения сплит-вакцины с ha гриппа
JP2023515829A (ja) 小児対象のための高用量インフルエンザワクチン

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240426

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240730

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240826

R150 Certificate of patent or registration of utility model

Ref document number: 7545955

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350